Research Article
Effect of Moxibustion on the Serum Levels of MMP-1, MMP-3, and VEGF in Patients with Rheumatoid Arthritis
Table 2
Clinical symptoms and RA serological disease markers after treatment.
| | Outcome measure | Treatment group (n = 34) | Control group (n = 32) | value |
| | Clinical symptoms | | | | | Morning stiffness score | 1.32 (1.27) | 2.44 (1.66) | 0.005† | | Tenderness index | 6.15 (5.00) | 10.25 (7.22) | 0.011† | | Swelling index | 3.09 (3.04) | 6.53 (6.49) | 0.042† | | VAS | 3.32 (1.65) | 4.72 (1.92) | 0.002† | | DAS28 | 4.40 (1.26) | 5.19 (1.39) | 0.017† |
| | RA serological disease markers | | | | | ESR (mm/60 min) | 38.47 (26.92) | 41.88 (27.36) | 0.612Δ | | CRP (mg/L) | 7.90 (8.40) | 7.06 (7.31) | 0.668Δ | | RF (IU/ml) | 130.22 (152.09) | 158.58 (195.78) | 0.549Δ |
|
|
Values are represented as mean (SD). † value by independent samples t test. value by Mann–Whitney U test. |
